TELA Bio Inc.

2.35
-0.10 (-4.08%)
At close: Mar 03, 2025, 3:59 PM
2.34
-0.21%
After-hours: Mar 03, 2025, 04:00 PM EST

Company Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy.

It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

The company markets its products through a single direct sales force, principally in the United States.

TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Bio Inc.
TELA Bio Inc. logo
Country United States
IPO Date Nov 8, 2019
Industry Medical - Devices
Sector Healthcare
Employees 227
CEO Antony Koblish

Contact Details

Address:
1 Great Valley Parkway
Malvern, Pennsylvania
United States
Website https://www.telabio.com

Stock Details

Ticker Symbol TELA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001561921
CUSIP Number 872381108
ISIN Number US8723811084
Employer ID 45-5320061
SIC Code 3841

Key Executives

Name Position
Antony Koblish Co-founder, President, Chief Executive Officer & Director
Paul Talmo Chief Technology Officer
Roberto E. Cuca J.D. Chief Financial Officer & Chief Operating Officer
D. Taylor Ocasio General Counsel & Corporate Secretary
Gregory A. Firestone Chief Commercial Officer
Jennifer Lou Armstrong Senior Vice President of Human Resources
Louisa Smith Investor Relations Contact Officer
Megan Smeykal Vice President, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer
Michael Leonard Senior Vice President of Technical Operations
Peter C. Murphy Chief Commercial Officer

Latest SEC Filings

Date Type Title
Feb 25, 2025 4 Filing
Feb 25, 2025 4 Filing
Feb 25, 2025 4 Filing
Feb 25, 2025 4 Filing
Feb 25, 2025 4 Filing
Feb 21, 2025 4 Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 13, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 12, 2025 SCHEDULE 13G Filing
Jan 31, 2025 SCHEDULE 13G/A [Amend] Filing